These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11720830)

  • 21. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.
    Saarto T; Vehmanen L; Blomqvist C; Elomaa I
    J Clin Oncol; 2008 Sep; 26(26):4289-95. PubMed ID: 18779616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.
    Shapiro CL; Manola J; Leboff M
    J Clin Oncol; 2001 Jul; 19(14):3306-11. PubMed ID: 11454877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors.
    McCune JS; Games DM; Espirito JL
    J Oncol Pharm Pract; 2005 Jun; 11(2):37-43. PubMed ID: 16460603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour.
    Beex LV; Mackenzie MA; Raemaekers JM; Smals AG; Benraad TJ; Kloppenborg PW
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):719-21. PubMed ID: 3383972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ovarian function and adjuvant chemotherapy for early breast cancer.
    Padmanabhan N; Wang DY; Moore JW; Rubens RD
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):745-8. PubMed ID: 3653192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients.
    Kim M; Kim H; Ahn SH; Tabatabaie V; Choi SW; Sohn G; Lee SB; Ko BS; Chung IY; Kim J; Lee JW; Son BH; Kim HJ
    Breast Cancer Res Treat; 2020 Apr; 180(3):657-663. PubMed ID: 32072339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
    Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
    J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
    Tiong V; Rozita AM; Taib NA; Yip CH; Ng CH
    World J Surg; 2014 Sep; 38(9):2288-96. PubMed ID: 24700093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients.
    Herrala J; Puolijoki H; Liippo K; Raitio M; Impivaara O; Tala E; Nieminen MM
    Bone; 1998 May; 22(5):577-82. PubMed ID: 9600795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.
    Pagani O; O'Neill A; Castiglione M; Gelber RD; Goldhirsch A; Rudenstam CM; Lindtner J; Collins J; Crivellari D; Coates A; Cavalli F; Thürlimann B; Simoncini E; Fey M; Price K; Senn HJ
    Eur J Cancer; 1998 Apr; 34(5):632-40. PubMed ID: 9713266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients.
    Saarto T; Blomqvist C; Risteli J; Risteli L; Sarna S; Elomaa I
    Br J Cancer; 1998 Jul; 78(2):240-5. PubMed ID: 9683300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
    Celi M; Balducci S; Schiappoli A; Caliumi C; Petramala L; Cerci S; Cotesta D; D'Erasmo E; Letizia C
    Ann Ital Med Int; 2003; 18(2):89-98. PubMed ID: 12886826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients.
    Poikonen P; Saarto T; Elomaa I; Joensuu H; Blomqvist C
    Eur J Cancer; 2000 Jan; 36(1):43-8. PubMed ID: 10741293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass.
    Filipponi P; Cristallini S; Policani G; Schifini MF; Casciari C; Garinei P
    Bone; 2000 Mar; 26(3):269-74. PubMed ID: 10710000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
    Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B; Mouridsen HT; Jensen MB
    Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer.
    Rodríguez-Rodríguez LM; Rodríguez-Rodríguez EM; Oramas-Rodríguez JM; Santolaria-Fernandez F; Llanos M; Cruz J; Martínez A; González-Reimers E; Gómez A; Batista N
    Breast Cancer Res Treat; 2005 Sep; 93(1):75-83. PubMed ID: 16184462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.
    Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Andersson M; Kamby C; Knoop AS;
    Cancer; 2010 May; 116(9):2081-9. PubMed ID: 20186830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.